| Ytd | -24.67% | |
| 1y | -5.36% |
| Open | 37.22 | Prev Close | 37.27 | Low | 36.25 | High | 37.45 | Mkt Cap | 1.38B |
| Vol | 390.20K | Avg Vol | 658.28K | EPS | -0.99 | P/E | N/A | Forward P/E | 13.49 |
| Beta | 0.25 | Short Ratio | 10.83 | Inst. Own | 58.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 41.29 | 200-d Avg | 41.32 | 1yr Est | 67.50 |
HROW News
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Ophthalmic disease management company Harrow Inc. (NASDAQ:HROW) on Thursday shared outcomes from a p
Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the larg
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and
U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26
Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate
Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000
Harrow (NASDAQ:HROW) reported quarterly losses of $(0.46) per share which missed the analyst consens
Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter ea
NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of oph
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 Comp
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (B
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (B
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of oph
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Har
INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch o
Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an F
Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic e
Harrow relaunches Verkazia for VKC treatment, targeting pediatric eye disease with a steroid-sparing
VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, pat
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of oph
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of opht
MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating
Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lo
Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript
Harrow NASDAQ: HROW executives said the company's first-quarter results were weighed down by a discr
U.S. stock futures lower, Nasdaq down 200 points. AST SpaceMobile shares dip 11% after reporting wor
Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising gui
Harrow (HROW) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate
Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000
Harrow (NASDAQ:HROW) reported quarterly losses of $(0.74) per share which missed the analyst consens
First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription perf
LogiCare3PL today announced it has been selected by Harrow, Inc. (NASDAQ:HROW) as a distribution par
B. Riley Securities analyst Mayank Mamtani reiterates Harrow (NASDAQ:HROW) with a Buy and lowers
The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and futu
Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lo
HC Wainwright & Co. analyst Yi Chen maintains Harrow (NASDAQ:HROW) with a Buy and raises the
Harrow stock drops after earnings miss and weak 2026 outlook, despite revenue growth and new product